中國飛鶴(06186.HK)溢價1.6%提購原生態牧業(01431.HK)
中國飛鶴(06186.HK)公布,提出要約收購原生態牧業(01431.HK)全數股權,每股作價0.63元,較原生態牧業上週四(3日)收市價0.62元溢價1.6%,原生態牧業於上週五開市前停牌。
相關收購涉及46.9億股及1.91億份購股權,涉資分別29.55億元及6,389.77萬元。中國飛鶴表示,收購可進一步加強公司於高端嬰幼兒配方奶粉產品市場的領導地位,另外亦可控制整條價值鏈及進一步提升經營效益。要約人無意於該等要約結束後將原生態牧業私有化,而擬維持該公司於聯交所主板之上市地位。
原生態牧業今早起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.